Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with Target = 'CDK2/Cyclin-E2'
TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.340nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601942(US11643416, Compound 42 | 4-((8'-methyl-7'-oxo-7',...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601941(US11643416, Compound 23 | (S)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601952(US11643416, Compound 54 | 2'-((4-(4-methylpiperazi...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601936(US11643416, Compound 4 | 4-((1'H-spiro[cyclohexane...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601946(US11643416, Compound 46 | 4-((1',3'-dimethyl-1'H- ...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601938(US11643416, Compound 18 | (R)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 2.70nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601954(US11643416, Compound 59 | 8'-methyl-2'-((4-((4-met...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601940(US11643416, Compound 5 | 4-((1'-methyl-1'H-spiro[c...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601960(US11643416, Compound 71 | 8'-methyl-2'-((4-(4- met...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601955(US11643416, Compound 61 | 7'-((4-(piperazine-1- ca...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601948(US11643416, Compound 50 | 6'-hydroxy-2'-((4-((4- m...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601944(US11643416, Compound 43 | 4-((6',8'-dimethyl-7'-ox...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601950(US11643416, Compound 52 | 7'-((4-(4-methylpiperazi...)
Affinity DataIC50: 4.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601939(US11643416, Compound 19 | (S)-4-((6'-methyl-8'-oxo...)
Affinity DataIC50: 4.80nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601962(US11643416, Compound 79 | 7'-((4-(S- methylsulfoni...)
Affinity DataIC50: 5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601949(US11643416, Compound 51 | 2'-((4-((4-methylpiperaz...)
Affinity DataIC50: 5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601961(US11643416, Compound 74 | 7'-((4-(morpholine-4- ca...)
Affinity DataIC50: 8nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM50511929(CHEMBL4452422)
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant CDK2/Cyclin E2 (unknown origin) expressed in baculovirus expression system using biotinylated-histone H1 as substrate measu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601947(US11643416, Compound 49 | 7'-((4-((4-methylpiperaz...)
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601937(US11643416, Compound 12 | 4-((1'-methyl-3'-oxo-2',...)
Affinity DataIC50: 13nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601956(US11643416, Compound 62 | N,N-dimethyl-4-((3'-oxo-...)
Affinity DataIC50: 14nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601945(US11643416, Compound 45 | 4-((3'-methyl-1'H-spiro[...)
Affinity DataIC50: 19nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601958(US11643416, Compound 64 | N-methyl-4-((3'-oxo-2',3...)
Affinity DataIC50: 23nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601957(US11643416, Compound 63 | 4-((3'-oxo-2',3'-dihydro...)
Affinity DataIC50: 33nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601963(US11643416, Compound 84 | 4-amino-N-(3'-oxo-2',3'-...)
Affinity DataIC50: 207nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601964(US11643416, Compound 91 | 4-amino-N-(6'-oxo-7',8'-...)
Affinity DataIC50: 287nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601959(US11643416, Compound 68 | 1-methyl-3-(4-((3'-oxo-2...)
Affinity DataIC50: 349nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/9/2025
Entry Details
Go to US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM50605448(CHEMBL5179617)
Affinity DataIC50: 464nMAssay Description:Inhibition of recombinant N-terminal GST/His6-fusion tagged human CDK2/Cyclin E2 expressed in Sf9 insect cells incubated for 20 mins followed by [33P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed